← Back to Search

CAR T-cell Therapy

CYAD-211 Immunotherapy for Multiple Myeloma (IMMUNICY-1 Trial)

Phase 1
Waitlist Available
Research Sponsored by Celyad Oncology SA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) below or equal 2
Documented diagnosis of MM with relapsed or refractory disease to at least two prior MM treatment regimens which should include exposure to IMiD and PIs either alone or in combination
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 36 days post-infusion.
Awards & highlights

IMMUNICY-1 Trial Summary

This trial is testing a new immunotherapy drug for people with relapsed or refractory multiple myeloma. The drug will be given after a lymphodepletion regimen with fludarabine and/or cyclophosphamide.

Who is the study for?
This trial is for adults with multiple myeloma that has come back or hasn't responded to at least two treatments, including IMiD and PIs. Participants must have measurable disease, be in decent physical shape (ECOG ≤2), and have good organ function. They can't join if they've had recent cancer treatment, CNS tumor involvement, a stem cell transplant too close to the study start date, or no response to previous BCMA-targeted therapy.Check my eligibility
What is being tested?
The IMMUNICY-1 study is testing CYAD-211's safety and effectiveness after patients receive lymphodepletion drugs Fludara (fludarabine) and/or Endoxan (cyclophosphamide). It aims to understand how this new therapy behaves in the body of those with relapsed/refractory multiple myeloma.See study design
What are the potential side effects?
Potential side effects may include reactions related to immune system activation such as fever or fatigue, complications from bone marrow suppression like infections or bleeding due to low blood counts, and possible damage to organs caused by the chemotherapy agents used for lymphodepletion.

IMMUNICY-1 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
My multiple myeloma has not responded to at least two treatments, including IMiD and PIs.

IMMUNICY-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 36 days post-infusion.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 days post-infusion. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of Dose Limiting Toxicities

IMMUNICY-1 Trial Design

1Treatment groups
Experimental Treatment
Group I: CYAD-211Experimental Treatment3 Interventions
Infusion post preconditioning non-myeloablative chemotherapy

Find a Location

Who is running the clinical trial?

Celyad Oncology SALead Sponsor
12 Previous Clinical Trials
1,281 Total Patients Enrolled
2 Trials studying Multiple Myeloma
158 Patients Enrolled for Multiple Myeloma

Media Library

CYAD-211 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04613557 — Phase 1
Multiple Myeloma Research Study Groups: CYAD-211
Multiple Myeloma Clinical Trial 2023: CYAD-211 Highlights & Side Effects. Trial Name: NCT04613557 — Phase 1
CYAD-211 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04613557 — Phase 1
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top